In short
Clinical trials investigating RO7284755 are studying treatment in people with BCG-unresponsive high-risk non-muscle invasive bladder cancer. The trials aim to assess safety, tolerability, dose selection, and anti-tumor activity in this target group. One study is completed and includes early-phase testing.
Key points
- Clinical trial data for RO7284755 focus on people with BCG-unresponsive high-risk non-muscle invasive bladder cancer. The listed study is a Phase 1 trial, so it mainly looks at safety, tolerability, and dose selection. Researchers also measured dose-limiting toxicities and complete response at 12 months. The trial included 23 participants and is marked as completed. The study also used cystoscopy, imaging, and pathology review to check for signs of cancer or disease progression.
Trial overview
The source data describe one interventional study of RO7284755 in people with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). The trial studied RO7284755 together with BCG treatment and was designed to learn whether the approach was safe and whether it showed signs of helping control the cancer.
Who was studied
The target population was people whose bladder cancer had not responded to BCG treatment and who had a high-risk form of NMIBC. This is a bladder cancer that has not grown into the muscle layer, but still has a higher chance of coming back or getting worse.
The study summary also shows that the trial looked for the absence of high-risk NMIBC or progressive disease, which means the researchers were watching for either no visible cancer or no worsening of the cancer.
Study phase and design
This was a Phase 1 interventional trial. Phase 1 studies are early studies that mainly focus on safety, tolerability, and finding a dose that can be used for later testing.
The trial summary says Phase I was used to evaluate the safety and tolerability of RO7284755 in combination with BCG, and to determine the maximum-tolerated dose and/or the recommended dose for extension. In simple terms, this means the researchers wanted to find a dose that people could receive with acceptable side effects before moving further in development.
What was measured
The main Phase I outcomes were adverse events, which are unwanted medical problems that happen during a study, and their severity was graded using the NCI CTCAE system. The trial also measured dose-limiting toxicities (DLTs), meaning side effects serious enough to stop a dose from being used as planned.
Another Phase I goal was to choose the recommended dose for extension (RDE) based on safety results. The Phase II part in Cohort A measured the complete response (CR) rate at 12 months, which means the share of participants with no visible cancer at that time point.
How results were checked
The study used cystoscopy, radiologic imaging, and retrospective central pathology review of cytology and biopsy to assess whether the cancer was still present or had progressed. Cystoscopy is a bladder exam with a thin camera, imaging means scans, and pathology review means checking tissue or cell samples under a microscope.
These checks helped the researchers judge both safety and anti-tumor activity in a structured way.
Trial status and size
The trial is listed as completed and included 23 participants. Based on the source data, this is the only RO7284755 trial provided, so the article focuses on this single completed study.